Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
Status:
Completed
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for
Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after
allogeneic hematopoietic stem cell transplantation in patients with haematological
malignancies